科济药业-B达成临床合作 计划2026年在华启动I期试验

美股速递
Jan 12

科济药业-B(CARsgen Therapeutics Holdings Ltd)宣布达成一项临床合作协议,将在中国开展I期临床试验。该试验计划于2026年启动,标志着公司在肿瘤免疫治疗领域的重要布局。此次合作旨在评估新型细胞治疗产品的安全性和初步疗效,为后续临床开发奠定基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10